FirstWord: Market Research Reports

... is vital for ensuring optimal performance levels of Medical Affairs teams. In Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and ... and timely EdgeMap and Need-Gap analysis of oncologists' perceptions of Medical Affairs teams highlighting good and bad performance and identifying ...

... market, equal to around 50 percent of all patients, noted Sanofi management last week (ViewPoints: Sanofi's Lemtrada flies the flag for patient power; can ... European physicians is encouraging (a trend supported by a pre-launch Physician Views poll run by FirstWord last year; Physician Views Poll Results – Sanofi's new multiple sclerosis treatment Lemtrada to be used ...

... , KAMs build relationships. Trends in Measuring and Rewarding KAM Team Performance provides a unique view of KAM teamwork situations, performance measurements, incentive schemes and the ... only make such measures effective and fair, but improve the whole performance review environment for KAMs? Trends in Measuring and Rewarding KAM Team ...

... . The commercial impact on Merck will be limited, ... Physician Views Poll Results: Lack of outcomes data, negative IMPROVE-IT results will ... Will you be encouraged to prescribe ezetimide ahead of PCSK9 inhibitors in difficult-to-treat patients following publication of positive data from the IMPROVE-IT study? What ...

... also Physician Views: What opportunity for biosimilar basal insulin?), we are polling US and EU5-based endocrinologists to gauge their assessment of new long-acting insulins ... Lantus sales will be flat next year (due most likely to greater rebating with payers) and the potential leverage their availability will ...

... insights from interviews with eight senior level industry executives, Optimal KOL Relationship Management – Leveraging the Digital Approach is an intelligent examination of evolving digital tools ... lifecycle can an eAdvisory Board contribute most to the development stakeholder relationships? Key features Access to the insights, opinions and analysis of eight ...

... have historically had minimal opportunity to leverage discounts from an oligopolistic ... well established players, it remains to be seen how comfortable physicians would be using a 'biosimilar' insulin developed by ... as 'interchangeable' with branded Lantus). Similarly, what percentage of patients would you be ...

... , were unveiled (ViewPoints: Investors respond in kind to impressive data for Bristol-Myers Squibb NSCLC immunotherapy). Checkmate-063 recruited 117 patients, each ... , noting that a 21 percent rate (or 18 percent for squamous patients) cited by Bristol-Myers Squibb stemmed from a database comprising only Medicare patients aged ...

There are a handful of reasons why sceptics are incredulous about Celgene's mongersen, this despite – or perhaps even because of – recently unveiled Phase II results ... . See ViewPoints: Expectations heightened for Celgene's Crohn's disease gamble. While there is some theoretical risk mongersen could cause fibrosis by raising TGF ...

The battle for market share in the US idiopathic pulmonary fibrosis (IPF) market is one that will be watched with much ...

... AstraZeneca and Nektar Therapeutics' Movantik, the first PAMORA product that is dosed orally (ViewPoints: Is AstraZeneca's motivation key to Movantik's commercial success?). ... daily, oral PAMORA drug indicated for OIC. A more bearish view of the market opportunity is shaped in part by retained concerns around ...

... Lucentis, while the availability of compounded Avastin, used as an alternative to Lucentis at a much cheaper cost, adds further confusion to the market outlook. Furthermore, a Physician Views ... therapies persists). FirstWord's Biosimilar Index reveals just one biosimilar Lucentis product in development; PF582 ...

... drugs would meet orphan drug criteria. Orphan Drugs are part of the clinical landscape and all stakeholders have valid interests which have to be addressed now. Orphan Drug Market Access: Payer Insights on the Present and Future offers insights from US and European healthcare payers and includes illustrative case ...

... whom subsequently need the anticoagulant action to be reversed due to bleeding or the requirement for surgery. Portola's assertion that andexanet alfa will meet ... who compete in this segment. Portola's recently unveiled Phase III data demonstrates the ability of andexanet alfa to reverse the effect of Eliquis, but ...

... ? Multiple Sclerosis – Oral therapy takes centre stage is a comprehensive Therapy Trends report packed with knowledgeable opinions and insights of 12 leading US and European KOLs on current ... , MD, is a preeminent MS clinician at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Co-Director, Multiple Sclerosis Care Center, Maimonides Medical Center Dr Robert Naismith, MD, Assistant Professor ...

Patient assistance programs (PAPs) are evolving in response to increasingly restrictive formularies and payer criticism. Patient Assistance Programs: Payer and Pharma Perspectives is a report that gives unique insight into payer ... and coupon models, payers have been increasingly resistant and critical of the new PAP schemes. FirstWord’s Patient Assistance Programs: Payer and Pharma Perspectives report ...

... benefit/positioning and support patient initiatives. Payer Insights: Hepatitis C, based on in-depth interviews with 12 leading healthcare payers in the US, is packed with hard-hitting, candid ... been matched by the opposition of healthcare payers at the cost. This report gives insights into what US healthcare payers really think about HCV drug ...

... -effect concerns linger, but post-AdCom consensus suggests these will act to shape how the product is utilised by physicians, rather than dictate whether ... ). Reflecting a key component of Novo Nordisk's obesity strategy – which is to target physicians they are familiar with and whom are familiar with ...

... patients? One presentation made at this week's ERS congress demonstrated that removal of the ICS component from a 'triple therapy' (comprising ICS, ... of exacerbations in moderate-to-severe COPD patients. Triple combinations are viewed by industry players as a potential paradigm-shifting therapy type – do you ...

... Yervoy (ipilimumab) and, if BRAF V600-mutation positive, a BRAF inhibitor (see also Physician Views Poll Results – Oncologists suggest Mekinist/Tafinlar combination will ... approval – the PD-1/PD-L1 inhibitors are expected to spearhead evolution of a multi-billion dollar market over the next decade – this Physician Views poll contains a second ...

... products, among the first in a new wave of medicines in late-stage development at Big Pharma for cardiovascular indications. Data from the PARADIGM-HF trial ... play a role in the company's price-setting calculus. Based on the new data, JP Morgan analyst Richard Vosser believes LCZ696 has 'multi-blockbuster ...

... 4/6 inhibitor class. Expectations for palbociclib were flying high in 2012 when Pfizer reported preliminary results from the Phase II PALOMA-1 trial showing the drug improved progression-free survival (PFS) by 18.6 months when added to Femara in postmenopausal women with oestrogen receptor (ER) positive, HER2 ...

... . As the Medical Affairs role evolves, more questions arise. And with each company defining the role differently, it is creating confusion. Reshaping Medical Affairs: delivering value to KOLs and ... improving performance of your Medical Affairs team Determine ways to improve stakeholder relationships and show value Find out how medical affairs can support the payer ...

... year. Questions have long been asked about whether and at what level of endogenous testosterone production does 'Low T' become a condition requiring ... in receiving testosterone therapy changed over the past 8 to 12 months? How has the controversy surrounding use of testosterone products (in particular the FDA ...

... market access teams are growing rapidly as the specific needs of key stakeholders grow ever greater. How do you structure and manage your market access team ...

... maintaining front line, product level access and education. In Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies, FirstWord ... marketed and four pipeline products Examination of physicians’ current usage of Medical Affairs teams services Key findings regarding the most and ...

... experts from the UK, Germany, Italy, France and Spain, FirstWord’s Oncology Market Access Europe – Payer and Industry Perspectives lays out the current – and growing – challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging ...

... where clinical unmet need remains high. That’s why FirstView’s ASCO 2014: Delegate Physicians Rate Influence and Impact report is a must-have ... of their time attending the presentation and poster sessions. In addition, physicians needed to see at least 100 patients in a typical month, including 10 patients ...

... neurologists to ascertain how practising physicians currently view and evaluate the gene therapy development space. Specifically we are asking them... How familiar they are with ... What they perceive to be the key benefits of gene therapy? What are their specific concerns with gene therapy? What is the highest ...

... has to up its patient–relations game. Essential insight in this new report: Pharma-Patient Engagement This closely argued and concise management report from FirstWord combines keen market observations with the insights of leading players in patients groups ...

... a biologic therapy? Whether, and to what extent, quality-of-life measures will be more important than secondary efficacy measures for differentiating new biologic therapies for severe asthma? What level of advantage, if any, reduced dosing frequency would provide for a biologic severe asthma ...

... by developments in the immuno-oncology (IO) space. Data presented at last year's ASCO meeting acted as the catalyst for bullish commercial projections for ... to identify key combinations in the IO space. Ahead of this year's ASCO meeting, FirstWord is polling US and EU5-based oncologists to ask them five key questions about ...

... on the cusp of driving a revolution in the treatment of US patients suffering from idiopathic pulmonary fibrosis (IPF). Positive Phase III data are expected to act as the ...

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how physicians value the role that medical affairs personnel play. Specifically we asked US and EU5-based oncologists: How important they view ...

... , the FDA published new guidance on the requirements for developing biosimilars for the US market – specifically focused on clinical pharmacology requirements ... , but potentially how they are used by physicians. In light of the FDA's new guidance, FirstWord is polling US-based oncologists and rheumatologists ...

... habits for Breo? How initial experience with Breo (patient/physician) has compared with Advair? How important a launch (regarding level ...

... , to legal challenges and questions about its profitability, The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events provides ... and most up-to-date access to recent and future events in the biosimilars market, including battles being waged over policy, regulatory, intellectual ...

... of loyalty to the MS treatments they prescribe? In what segment of the MS market is their loyalty to particular products strongest? What a new therapy would need to demonstrate ... ) they believe is the most important differentiator between approved MS therapies? What commercial attribute they believe is the most important differentiator between ...

... early access to a new cancer product, but a number of developers have also highlighted notable benefits derived from the process. To assess the view of expanded access programmes from the position of the physician community, FirstWord is polling oncologists based in the ...

... enabler in opening up the conversations and interactions between patients and physicians, potentially giving the latter a greater opportunity to prioritise treatment ... they are of wearable health technologies What they perceive to be the key benefits What concerns they have What they believe to be the biggest ...

... have their own particular views on how this resource can be used to improve the treatment of patients in the future? Are they aware of the ... physician perceptive towards real-world data, FirstWord polled 192 oncologists based in the US and EU5. Specifically we asked them How aware they are ...

... turn to the commercial opportunity for Afrezza – see ViewPoints: Focus switches to commercial outlook for MannKind's inhaled insulin Afrezza. On the face of it, an effective inhaled insulin product would be a welcome addition to the diabetes armatorium, a view shared by last ...

... a hypothetical patient to a 'shuttlecock' – who is assessed and subsequently transferred to another physician on multiple occasions – patient-centricity 'seeks to focus medical attention on the ... , FirstWord is polling pulmonologists based in the US and EU5 to assess how physicians perceive patient-centric support services. Specifically, FirstWord is asking pulmonologists ...

... are physicians ready for biosimilars and is the industry doing enough to educate who is arguably the key stakeholder in this market? As physician ... for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say majority of physicians, but caveats remain In a ...

... represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the ... will shape the future market. Key Benefits Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained ...

... is not, significant. That is where the Biosimilar Index comes in. A new force in biosimilar and NCB drug and market tracking FirstView’s Biosimilar Index is a new, comprehensive drug intelligence ... both on-going tracking of development and interpretation of the commercial and clinical significance. Two class beating services in one subscription! Biosimilar Index: Pipeline Database ...

... documented access and pricing issues, various nuances within the hepatitis C treatment paradigm continue to be explored. Furthermore, data due to be presented at EASL ... efficacy and convenience and provide a cure for hepatitis C in the vast majority of patients. Although hepatitis is likely to be the key focus for most ...

... respectively, in 2013, it is not surprising to see both companies implementing life-cycle management strategies in the key US market. The performance of the two products ... earlier Physician Views polls run by FirstWord did support the view that Teva would meet its expectations. Sentiment towards the strategy ...

... KOL analysis of NSCLC treatments, development and competition, KOL Insight: Non-small cell lung cancer is an essential tool for keeping abreast of events that will shape ... Developments in the treatment of NSCLC are progressing rapidly. In KOL Insight: Non-small cell lung cancer, you will: Gain an invaluable overview into the most dynamic ...

... comprehensive FirstWord research is available in two comprehensive modules: The KOL Insight: Multiple Sclerosis module provides a complete review and is enhanced with ... the date of purchase Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report ...